Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.

Jiménez-Yuste V, Álvarez-Román MT, Martín-Salces M, De la Corte-Rodríguez H, Altisent C, Parra R, Núñez R, Pérez R, García-Candel F, Bonanad S, Querol F, Alonso N, Fernández-Mosteirín N, López-Ansoar E, García-Frade LJ, Bermejo N, Pérez-González N, Gutiérrez-Pimentel MJ, Martinoli C, Fernández-Arias I, Kim HK.

Haemophilia. 2019 Jan;25(1):144-153. doi: 10.1111/hae.13628. Epub 2018 Nov 16.

PMID:
30444298
2.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellin S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Quismondo NC, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.

Haematologica. 2019 Mar;104(3):587-598. doi: 10.3324/haematol.2018.203166. Epub 2018 Oct 25.

3.

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Pérez-Rodríguez A, Batlle J, Corrales I, Borràs N, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Navarro N, Altisent C, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Castro Quismondo N, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio M, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Batlle F, Vidal F, López-Fernández MF.

PLoS One. 2018 Jun 20;13(6):e0197876. doi: 10.1371/journal.pone.0197876. eCollection 2018.

4.

Diagnostic delay in acquired haemophilia: Analysis of causes and consequences in a 20-year Spanish cohort.

Pardos-Gea J, Fernández-Díaz N, Parra R, Cortina V, Altisent C.

Haemophilia. 2018 May;24(3):e163-e166. doi: 10.1111/hae.13499. Epub 2018 May 6. No abstract available.

PMID:
29732654
5.

Moderate and severe haemophilia in Spain: An epidemiological update.

Aznar JA, Altisent C, Álvarez-Román MT, Bonanad S, Mingot-Castellano ME, López MF.

Haemophilia. 2018 May;24(3):e136-e139. doi: 10.1111/hae.13462. Epub 2018 Mar 26. No abstract available.

PMID:
29578308
6.

Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A.

Thromb Haemost. 2018 Mar;118(3):451-460. doi: 10.1055/s-0038-1624581. Epub 2018 Feb 15.

7.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
8.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Vidal F, Corrales I.

Haematologica. 2017 Dec;102(12):2005-2014. doi: 10.3324/haematol.2017.168765. Epub 2017 Sep 29.

9.

Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA.

Martorell L, Luce E, Vazquez JL, Richaud-Patin Y, Jimenez-Delgado S, Corrales I, Borras N, Casacuberta-Serra S, Weber A, Parra R, Altisent C, Follenzi A, Dubart-Kupperschmitt A, Raya A, Vidal F, Barquinero J.

J Thromb Haemost. 2017 Nov;15(11):2188-2197. doi: 10.1111/jth.13808. Epub 2017 Sep 25.

PMID:
28834196
10.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
11.

The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders.

Jiménez-Yuste V, Kruse-Jarres R, Rangarajan S, Altisent C.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S1. doi: 10.1160/TH16-01-0047. Epub 2016 Aug 16. No abstract available.

PMID:
27528277
12.

Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.

Windyga J, Dolan G, Altisent C, Katsarou O, López Fernández MF, Zülfikar B; EHTSB.

Haemophilia. 2016 Sep;22(5):739-51. doi: 10.1111/hae.12955. Epub 2016 Jun 13.

PMID:
27292438
13.

Sodium content in products used to treat haemophilia.

Altisent C, Martorell M, de la Sierra A.

Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26. No abstract available.

PMID:
27228069
14.

Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

Korth-Bradley JM, Rendo P, Smith L, Altisent C.

Clin Ther. 2016 Apr;38(4):936-44. doi: 10.1016/j.clinthera.2016.02.015. Epub 2016 Mar 8.

PMID:
26969334
15.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Álvarez-Roman MT, Voigt C, Blackman N, Jacobs I; PROLONG-9FP Investigators Study Group.

Blood. 2016 Apr 7;127(14):1761-9. doi: 10.1182/blood-2015-09-669234. Epub 2016 Jan 11.

16.

Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes.

Altisent C, Martorell M, Crespo A, Casas L, Torrents C, Parra R.

Haemophilia. 2016 Mar;22(2):218-224. doi: 10.1111/hae.12792. Epub 2015 Aug 28.

PMID:
26315845
17.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.

Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F.

Thromb Haemost. 2016 Jan;115(1):40-50. doi: 10.1160/TH15-04-0282. Epub 2015 Aug 6.

PMID:
26245874
18.

Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.

Windyga J, Dolan G, Altisent C, Katsarou O, López Fernández MF, Zülfikar B; EHTSB.

Haemophilia. 2016 Jan;22(1):110-20. doi: 10.1111/hae.12763. Epub 2015 Jul 24.

PMID:
26207933
19.

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.

García-Dasí M, Aznar JA, Jiménez-Yuste V, Altisent C, Bonanad S, Mingot E, Lucía F, Giménez F, López MF, Marco P, Pérez R, Fernández MÁ, Paloma MJ, Galmes B, Herrero S, García-Talavera JA.

Haemophilia. 2015 Jul;21(4):458-64. doi: 10.1111/hae.12618. Epub 2015 Feb 4.

PMID:
25649244
20.

Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.

Nijdam A, Altisent C, Carcao MD, Cid AR, Claeyssens-Donadel S, Kurnik K, Ljung R, Nolan B, Petrini P, Platokouki H, Rafowicz A, Thomas AE, Fischer K; PedNet and CANAL study groups.

Haematologica. 2015 Mar;100(3):e84-6. doi: 10.3324/haematol.2014.115709. Epub 2014 Dec 19. No abstract available.

21.

International cross-cultural validation study of the Canadian haemophilia outcomes: kids' life assessment tool.

McCusker PJ, Fischer K, Holzhauer S, Meunier S, Altisent C, Grainger JD, Blanchette VS, Burke TA, Wakefield C, Young NL.

Haemophilia. 2015 May;21(3):351-7. doi: 10.1111/hae.12597. Epub 2014 Dec 4.

PMID:
25471939
22.

Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients.

de la Morena-Barrio ME, Di Michele M, Lozano ML, Rivera J, Pérez-Dueñas B, Altisent C, Sevivas T, Vicente V, Jaeken J, Freson K, Corral J.

Thromb Res. 2014 Mar;133(3):412-7. doi: 10.1016/j.thromres.2013.12.024. Epub 2013 Dec 21.

PMID:
24388574
23.

GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients.

de la Morena-Barrio ME, Hernández-Caselles T, Corral J, García-López R, Martínez-Martínez I, Pérez-Dueñas B, Altisent C, Sevivas T, Kristensen SR, Guillén-Navarro E, Miñano A, Vicente V, Jaeken J, Lozano ML.

Orphanet J Rare Dis. 2013 Oct 20;8:170. doi: 10.1186/1750-1172-8-170.

24.

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group.

Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.

25.

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).

Napolitano M, Giansily-Blaizot M, Dolce A, Schved JF, Auerswald G, Ingerslev J, Bjerre J, Altisent C, Charoenkwan P, Michaels L, Chuansumrit A, Di Minno G, Caliskan U, Mariani G.

Haematologica. 2013 Apr;98(4):538-44. doi: 10.3324/haematol.2012.074039. Epub 2013 Feb 12.

26.

Emerging viral infections‑-a potential threat for blood supply in the 21st century.

de Mendoza C, Altisent C, Aznar JA, Batlle J, Soriano V.

AIDS Rev. 2012 Oct-Dec;14(4):279-89. Review.

PMID:
23258302
27.

Continuous infusion in haemophilia: current practice in Europe.

Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K; European Haemophilia Treatment Standardisation Board.

Haemophilia. 2012 Sep;18(5):753-9. doi: 10.1111/j.1365-2516.2012.02810.x. Epub 2012 Apr 25.

PMID:
22530687
28.

Advances in hemophilia care: report of two symposia at the Hemophilia 2010 World Congress.

Dolan G, Cruz JA, Steinhagen-Thiessen E, Kessler C, Haaning J, Lemm G, Altisent C, Guerrero C, Hermans C, Riske B, Bolton-Maggs P.

Adv Ther. 2012 Apr;29 Suppl 1:1-16. doi: 10.1007/s12325-012-0010-3. Epub 2012 Mar 16.

PMID:
22467446
29.

Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study.

Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarrès M, Ordi-Ros J.

Haemophilia. 2012 Sep;18(5):789-93. doi: 10.1111/j.1365-2516.2012.02772.x. Epub 2012 Mar 19.

PMID:
22429259
30.

High-throughput molecular diagnosis of von Willebrand disease by next generation sequencing methods.

Corrales I, Catarino S, Ayats J, Arteta D, Altisent C, Parra R, Vidal F.

Haematologica. 2012 Jul;97(7):1003-7. doi: 10.3324/haematol.2011.055285. Epub 2012 Feb 7.

31.

Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.

Lopez-Vilchez I, Hedner U, Altisent C, Diaz-Ricart M, Escolar G, Galan AM.

Am J Pathol. 2011 Jun;178(6):2938-48. doi: 10.1016/j.ajpath.2011.02.026.

32.

The optimal mode of delivery for the haemophilia carrier expecting an affected infant: further considerations.

Altisent C, Martorell M, Vidal F, Sánchez MA, Parra R.

Haemophilia. 2011 Sep;17(5):818-9. doi: 10.1111/j.1365-2516.2011.02505.x. Epub 2011 Mar 4. No abstract available.

PMID:
21371199
33.

The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients' platelets and leukocytes.

Corrales I, Ramírez L, Altisent C, Parra R, Vidal F.

J Thromb Haemost. 2011 Apr;9(4):679-88. doi: 10.1111/j.1538-7836.2011.04204.x.

34.

Integration of molecular and clinical data of 40 unrelated von Willebrand Disease families in a Spanish locus-specific mutation database: first release including 58 mutations.

Corrales I, Ramírez L, Ayats J, Altisent C, Parra R, Vidal F.

Haematologica. 2010 Nov;95(11):1982-4. doi: 10.3324/haematol.2010.028977. Epub 2010 Aug 26. No abstract available.

35.

The 'royal disease' mutation in a Spanish patient.

Ramírez L, Altisent C, Parra R, Vidal F.

J Thromb Haemost. 2010 Oct;8(10):2316-7. doi: 10.1111/j.1538-7836.2010.03977.x. No abstract available.

36.

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K; European Haemophilia Therapy Standardisation Board.

Haemophilia. 2010 Sep 1;16(5):747-66. doi: 10.1111/j.1365-2516.2010.02231.x. Epub 2010 Apr 14. Review.

PMID:
20398077
37.

Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations.

Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, Klamroth R, Richards M, White B, Dolan G; European Haemophilia Therapy Standardisation Board.

Haemophilia. 2009 May;15(3):639-58. Review.

PMID:
19444969
38.

Recovery of recombinant factor IX determined in clinical practice.

Martorell M, Altisent C, Parra R.

Haemophilia. 2009 May;15(3):840-2. doi: 10.1111/j.1365-2516.2009.02000.x. No abstract available.

PMID:
19432932
39.

Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene.

Corrales I, Ramírez L, Altisent C, Parra R, Vidal F.

Thromb Haemost. 2009 Mar;101(3):570-6.

PMID:
19277422
40.

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.

Rentz A, Flood E, Altisent C, Bullinger M, Klamroth R, Garrido RP, Scharrer I, Schramm W, Gorina E; Members of the HAEMO-QoL-A Steering Committee.

Haemophilia. 2008 Sep;14(5):1023-34. doi: 10.1111/j.1365-2516.2008.01812.x. Epub 2008 Jul 28.

PMID:
18665853
41.

Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.

Batlle J, Villar A, Liras A, Alonso C, Altisent C, Brito D, Moreno M, Lucía F, Sedano C, Prieto M, Calvente N, Aznar JA, Jiménez V, Soriano V, Martorell JR, Iruín G, Bergua JM, Aguilar C.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):333-40. doi: 10.1097/MBC.0b013e328300c814. Review.

PMID:
18600079
42.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V.

Haemophilia. 2007 Sep;13(5):502-7.

PMID:
17880436
43.

Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.

Richards M, Altisent C, Batorova A, Chambost H, Dolan G, de Moerloose P, Fraga M, Hermans C, Karafoulidou A, Klamroth R, Lassila R, Rothschild C.

Haemophilia. 2007 Sep;13(5):473-9.

PMID:
17880432
44.

A versatile strategy for preimplantation genetic diagnosis of haemophilia A based on F8-gene sequencing.

Sánchez-García JF, Gallardo D, Navarro J, Márquez C, Gris JM, Sánchez MA, Altisent C, Vidal F.

Thromb Haemost. 2006 Dec;96(6):839-45.

PMID:
17139381
45.

Acquired haemophilia A: successful treatment with immunosuppression, methylprednisolone pulses and oral cyclosporin.

Pardos-Gea J, Ordi-Ros J, Altisent C, Balada E, Pérez-López J, Vilardell M.

Thromb Haemost. 2006 Apr;95(4):735-7. No abstract available.

PMID:
16601847
46.

Von Willebrand gene tracking by single-tube automated fluorescent analysis of four short tandem repeat polymorphisms.

Vidal F, Julià A, Altisent C, Puig L, Gallardo D.

Thromb Haemost. 2005 May;93(5):976-81.

PMID:
15886817
47.

[Recombinant activated factor VII in uncontrolled hemorrhage].

Colomina MJ, Altisent C, Guerrero E, Godet C.

Med Clin (Barc). 2005 Feb 5;124(4):156. Spanish. No abstract available.

PMID:
15713248
48.

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.

Stieltjes N, Altisent C, Auerswald G, Négrier C, Pouzol P, Reynaud J, Roussel-Robert V, Savidge GF, Villar A, Schulman S.

Haemophilia. 2004 Sep;10(5):452-8.

PMID:
15357770
49.

Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003.

Mathew P, Altisent C.

Blood Coagul Fibrinolysis. 2004 Jun;15 Suppl 2:S1-3. Review. No abstract available.

PMID:
15322449
50.

Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia.

Arranz P, Remor E, Quintana M, Villar A, Díaz JL, Moreno M, Monteagudo J, Ugarriza A, Soto I, Pérez R, Chacón J, García-Luaces M, Cid A, Balda I, López MF, Gutíerrez MJ, Martínez E, Marrero C, Prieto M, Sedano C, Vaca R, Altisent C, Hernández-Navarro F; Hemofilia-QoL Group.

Haemophilia. 2004 Jul;10(4):376-82.

PMID:
15230953

Supplemental Content

Loading ...
Support Center